What's Going On With Cancer-Focused Immix Biopharma Stock Today?
Portfolio Pulse from Vandana Singh
Immix Biopharma Inc (NASDAQ:IMMX) announced updated data from its ongoing Phase 1b/2 NEXICART-1 study of NXC-201, a CAR-T cell therapy. The data showed a 95% overall response rate in relapsed/refractory multiple myeloma patients who were not exposed to prior BCMA-targeted therapy. The company's shares are up 23.40% at $4.22.
October 02, 2023 | 6:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immix Biopharma's ongoing study of NXC-201 shows promising results, leading to a rise in the company's stock price.
The positive results from the ongoing study of NXC-201 have increased investor confidence in Immix Biopharma, leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100